Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 570 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT06920251RecruitingPhase 2
Preventing CMV Infection During Elranatamab Treatment for Myeloma
This trial tests whether giving letermovir (a medication to prevent CMV infection) is safe and effective for people with relapsed/refractory multiple myeloma who are starting elranatamab therapy. It is for patients who have already had several prior treatments and have been exposed to CMV in the past.
SeoulAges 19 years+ - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT06908629Recruiting
Helping Detroit cancer survivors with social needs
This study looks at how social needs (like finding enough food) affect cancer survivors in the Detroit area. If you join, researchers will work to connect you with resources that might help.
Detroit, MichiganAges 18 years+ - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age - NCT06870760Recruiting
Early blood cancer detection in Charlotte firefighters
This study looks at firefighters to find early signs of blood cancers before they become serious. It aims to learn how to catch these cancers earlier, so they can be treated sooner.
Charlotte, North CarolinaAges 40–49 - NCT06464991RecruitingPhase 3
Eque-cel for Lenalidomide-Refractory Multiple Myeloma
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
BeijingAges 18–75 - NCT06760052Recruiting
Plasma Cell Disorder Long-Term Registry Study
This study creates a long-term database of patients with plasma cell disorders (such as multiple myeloma) to improve future care. You would be helping doctors learn more about these conditions by sharing your records over time.
Shanghai, Shanghai MunicipalityAges 19–99 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+ - NCT06559033Recruiting
Gene study for multiple myeloma or MGUS patients
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
RouenAges 18 years+ - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+ - NCT06500884RecruitingPhase 2
Preventing mouth problems from GPRC5D therapy in myeloma
This study tests a preventive treatment for mouth or taste problems that can be caused by a newer type of multiple myeloma therapy. It aims to help people who have already tried several standard treatments and whose disease is still active.
San Francisco, CaliforniaAges 18 years+ - NCT06477783Recruiting
Teclistamab and talquetamab for advanced multiple myeloma
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
Bonheiden, AntwerpenAges 18 years+ - NCT06483100RecruitingPhase 2
Elranatamab after stem cell transplant for multiple myeloma
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
St Louis, MissouriAges 18 years+ - NCT06487247Recruiting
Home transfusion program for blood cancer patients
This trial offers red blood cell or platelet transfusions at home for people with blood cancer who are no longer responding to treatment. It aims to improve comfort and quality of life by avoiding hospital visits.
Boston, MassachusettsAges 18 years+ - NCT06133426Recruiting
Connected scales for blood cancer patients at home
This trial tests if using a connected scale to monitor your weight at home can help your doctors manage your treatment for aggressive non-Hodgkin's lymphoma or multiple myeloma. It may also apply if you need a stem cell transplant (autograft) for these conditions.
ParisAges 18 years+ - NCT06409767Recruiting
Early warning system for blood cancer patients on chemo or transplant
This study tests whether a special early warning system can help doctors spot problems sooner in people with blood cancers who are getting strong chemo or a stem cell transplant. The goal is to improve outcomes by catching complications early.
AmiensAges 18 years+ - NCT06383143Recruiting
Improving diagnosis and care for AL amyloidosis and related conditions
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
BariAges 18–99 - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06357754Recruiting
Testing tumor samples after BMS cell therapy and a second cancer
This trial offers testing of tumor samples for people who developed a new, different cancer after receiving a Bristol-Myers Squibb gene-modified cell therapy. The goal is to understand the genetics of that new cancer and see if it relates to the prior treatment.
Portland, OregonAges Any age - NCT06340646Recruiting
Washington University cancer gene study
This study collects genetic information from people with certain cancers to learn more about cancer risks and outcomes. It may help researchers understand how genes affect cancer in different groups.
St Louis, MissouriAges 18 years+ - NCT06296368Recruiting
A tool to help older adults make cancer care decisions
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
Chapel Hill, North CarolinaAges 60 years+ - NCT06262789Recruiting
Returning to work after blood cancer treatment
This study helps people who have finished treatment for a blood cancer (like leukemia or lymphoma) figure out the best way to return to work. It looks at what support might be needed during this transition.
AngersAges 18–55
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 570 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.